Anthem Biosciences FY26 KPI Disclosure: Revenue Growth, Margins

• Anthem Biosciences discloses audited KPIs for FY26 showing ₹21.24 billion revenue and 15.17% YoY growth.
• Material margin improved to ₹13.12 billion with EBITDA margin at 41.01% and PAT margin at 25.95%.
• CRDMO segment contributed 83% of revenue with net cash position strengthening to ₹13.74 billion.
• K.P. Rao & Co. verified KPIs including operational metrics like 2,282 employees and 198 net working capital days.